A new paradigm of cancer immunotherapy based on [18F]FDG and anti-PD-L1 mAb combination

被引：0
|
作者：
Wen, Xuejun [1 ]
Chen, Xiaoyuan [1 ]
Zhang, Xianzhong [1 ]
Guo, Zhide [1 ]
机构：
[1] Xiamen Univ, Xiamen, Peoples R China
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2022年 / 108卷
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P-312
引用
收藏
页码：S219 / S220
页数：2
相关论文
共 50 条
  • [31] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
    Nakayama, Yuko
    Mimura, Kosaku
    Tamaki, Tomoaki
    Shiraishi, Kensuke
    Kua, Ley-Fang
    Koh, Vivien
    Ohmori, Masato
    Kimura, Ayako
    Inoue, Shingo
    Okayama, Hirokazu
    Suzuki, Yoshiyuki
    Nakazawa, Tadao
    Ichikawa, Daisuke
    Kono, Koji
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (06) : 2030 - 2038
  • [33] Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
    Grapin, Mathieu
    Richard, Corentin
    Limagne, Emeric
    Boidot, Romain
    Morgand, Veronique
    Bertaut, Aurelie
    Derangere, Valentin
    Laurent, Pierre-Antoine
    Thibaudin, Marion
    Fumet, Jean David
    Crehange, Gilles
    Ghiringhelli, Francois
    Mirjolet, Celine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
    Garces, Alvaro H. Ingles
    Au, Lewis
    Mason, Robert
    Thomas, Jennifer
    Larkin, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 695 - 708
  • [35] In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh, Sandrine
    Matias, Margarida
    Palomar, Virginia
    Dercle, Laurent
    Lanoy, Emilie
    Soria, Jean-Charles
    Postel-Vinay, Sophie
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 65 - 74
  • [36] Intestinal microbiota may dynamically facilitate the anti-PD-L1 immunotherapy
    Xue, Jia
    Wang, Zhun
    Guo, Sheng
    Cai, Jie
    Ouyang, Davy
    Cai, Bin
    Chen, Gang
    Liu, Jie
    Dong, Xin
    Li, Henry
    CANCER RESEARCH, 2017, 77
  • [37] Anti-PD-L1 inhibitor durvalumab in bladder cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (07): : E275 - E275
  • [38] FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
    Lu, Lu
    Jiang, Yi-Xin
    Liu, Xiao-Xia
    Jin, Jin-Mei
    Gu, Wen-Jie
    Luan, Xin
    Guan, Ying-Yun
    Zhang, Li-Jun
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [39] Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy
    Xu, Mengxin
    Han, Yuxiang
    Liu, Guizhong
    Xu, Yang
    Duan, Dongban
    Liu, Hui
    Du, Felix
    Luo, Peter
    Liu, Zhibo
    MOLECULAR PHARMACEUTICS, 2018, 15 (10) : 4426 - 4433
  • [40] Oral delivery of anti-PD-L1 antibody for cancer immunotherapy against orthotopic colorectal tumors
    Chen, Linfu
    Zhang, Lin
    Zhao, Rui
    Shen, Jingjing
    Wang, Yingyao
    Zhu, Jiafei
    Fang, Huapan
    Liu, Nanhui
    Wang, Cheng
    Wei, Ting
    Chai, Yu
    Li, Maoyi
    Wu, Chenghao
    Chen, Qian
    Liu, Zhuang
    NANO TODAY, 2023, 50
12345